Department of Health and Human Services
National Institutes of Health
Toggle navigation
Search
Home
About the Clinical Center
Clinical Trials & You
Participate in a Study
Referring a Patient
How to Search
Contact Us
Search the Studies
Go Back
Searched Result
92 Studies found from all possible combinations of your search terms. Select a protocol that you wish to review.
Protocol Number
Title
Protocol Status
Min-Max Age
Institute
Keywords
08-H-0105
Natural History Study of Monoclonal B Cell Lymphocytosis (MBL), Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL), Lymphoplasmacytic Lymphoma (LPL)/Waldenstrom Macroglobulinemia (WM), and Splenic Marginal Zone Lymphoma (SMZL)
Participants currently recruited/enrolled
18-125 Years
NHLBI
Splenic Marginal Zone Lymphoma
000326-H
A Phase 1, Dose Escalation, Safety and Tolerability Study of NX- 2127, a Bruton's Tyrosine Kinase (BTK) Degrader, in Adults with Relapsed/Refractory B-cell Malignancies
Participants currently recruited/enrolled
18-125 Years
NHLBI
Marginal Zone Lymphoma
20-C-0162
A Phase 1 Study of Venetoclax with Obinutuzumab and Magrolimab (VENOM) in Relapsed and Refractory Indolent B-cell Malignancies
Participants currently recruited/enrolled
18-125 Years
NCI
Marginal Zone Lymphoma
17-C-0048
Anti-CD30 CAR T Cells with Fully-human Binding Domains for Treating CD30-expressing Lymphomas Including Anaplastic Large Cell Lymphomas
Completed Study; data analyses ongoing
18-73 Years
NCI
Zone Lymphoma
93-C-0133
Dose-Adjusted EPOCH Chemotherapy and Rituximab (CD20+) in Adults and Children with Previously Untreated Patients with Aggressive Non-Hodgkin's Lymphoma
No longer recruiting/follow-up only
12-125 Years
NCI
Zone Lymphoma
000923-H
Observational Study of Cardiac Arrhythmias in Subjects Treated with BTK Inhibitors
Participants currently recruited/enrolled
18-110 Years
NHLBI
Lymphoma
000633-C
Phase 1/2 Study of VIP152, Venetoclax, and Prednisone (VVIP) in Relapsed/Refractory Lymphoid Malignancies
Participants currently recruited/enrolled
18-125 Years
NCI
Lymphoma
000631-C
Investigation of the Cognitive Aftereffects of Neurotoxicity in Children and Young Adults with Relapsed/Refractory Hematologic Malignancies who Receive CAR T-cell Therapy
Recruitment has not started
5-125 Years
NCI
Lymphoma
000613-C
Phase I/II Trial to Determine the Lowest Effective Dose of Post-Transplantation Cyclophosphamide in Combination with Sirolimus and Mycophenolate Mofetil as Graft-Versus-Host Disease Prophylaxis after Reduced Intensity Conditioning and Peripheral Blood St
Participants currently recruited/enrolled
12-125 Years
NCI
Lymphoma
000516-C
Phase 1 Study of Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (VIPOR) for Diffuse Large B-cell Lymphoma involving the Central Nervous System
Participants currently recruited/enrolled
18-125 Years
NCI
Lymphoma
000489-C
Phase I/II Study Using Prophylactic Donor Lymphocyte Infusion Early Post-Transplant After Allogeneic Hematopoietic Cell Transplantation Using Post-Transplantation Cyclophosphamide for High-Risk Hematologic Malignancies
Clinical hold/Recruitment or enrollment suspended
12-125 Years
NCI
Lymphoma
000444-H
Vaccine Responses in Patients with B Cell Malignancies
Participants currently recruited/enrolled
18-125 Years
NHLBI
Lymphoma
000337-C
Natural History Study of KSHV-Associated Multicentric Castleman's Disease
Participants currently recruited/enrolled
18-125 Years
NCI
Lymphoma
000324-C
Phase 1/2 Dose Escalation Study of CD19/CD22 Bicistronic Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults with Recurrent or Refractory CD19/CD22-expressing B Cell Malignancies
Participants currently recruited/enrolled
3-35 Years
NCI
Lymphoma
000274-C
Phase I Trial of Pomalidomide and Dose-Adjusted EPOCH +/- Rituximab for HIV-Associated Lymphomas
Participants currently recruited/enrolled
18-125 Years
NCI
Lymphoma
000193-C
Phase 1 Study of Copanlisib with Dose-adjusted EPOCH-R in Relapsed and Refractory Burkitt Lymphoma and other High-Grade B-cell Lymphomas
Clinical hold/Recruitment or enrollment suspended
18-125 Years
NCI
Lymphoma
000115-C
A Trial of the Safety and Immunogenicity of the COVID-19 Vaccine (mRNA-1273) in Participants with Hematologic Malignancies and Various Regimens of Immunosuppression, and in Participants with Solid Tumors on PD1/PDL1 Inhibitor Therapy, Including Booster D
Participants currently recruited/enrolled
18-125 Years
NCI
Lymphoma
000067-C
Understanding the Patient Experience: Symptom Burden in Pediatric Patients Receiving Chimeric Antigen Receptor (CAR) T-cell Therapy
Participants currently recruited/enrolled
2-125 Years
NCI
Lymphoma
21-C-0023
A Phase I Study of Pomalidomide and Nivolumab in Patients with Virus-Associated Malignancies With or Without HIV
Participants currently recruited/enrolled
18-125 Years
NCI
Lymphoma
21-C-0014
Phase 1 Study of Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid in Combination with Polatuzumab (ViPOR-P) in Relapsed/Refractory B-cell Lymphoma
Participants currently recruited/enrolled
18-125 Years
NCI
Lymphoma
20-N-0019
The Effect of Vorinostat on ACTH Producing Pituitary Adenomas in Cushing's Disease
Participants currently recruited/enrolled
18-125 Years
NINDS
Lymphoma
20-H-0016
Duvelisib for Ibrutinib-Resistant Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
Completed Study; data analyses ongoing
18-125 Years
NHLBI
Lymphoma
20-C-0127
A Phase 1 Study of Romidepsin, CC-486 (5-azacitidine), dexamethasone, and lenalidomide (RAdR) for relapsed/refractory T-cell malignancies
Participants currently recruited/enrolled
18-125 Years
NCI
Lymphoma
20-C-0062
A phase 1b Study of Nivolumab in Patients with Autoimmune Disorders and Advanced Malignancies (AIM-NIVO)
Participants currently recruited/enrolled
18-125 Years
NCI
Lymphoma
20-C-0011
Phase 1 Study of Recombinant Human IL-15 (rhIL-15) and Mogamulizumab for Patients with Refractory or Relapsed Adult T-Cell Leukemia and Mycosis Fungoides/Sezary Syndrome
Completed Study; data analyses ongoing
18-125 Years
NCI
Lymphoma
19-H-0001
Response to the SHINGRIX Varicella Zoster Virus (VZV) Vaccine in Chronic Lymphocytic Leukemia (CLL) Patients that are Treatment Na(SqrRoot) ve or Receiving Bruton s-tyrosine Kinase Inhibitor (BTK-I) Therapy
No longer recruiting/follow-up only
18-125 Years
NHLBI
Lymphoma
19-C-0116
A Phase 2 Study of Acalabrutinib with DA-EPOCH-R or R-CHOP for Patients with Untreated Diffuse Large B-cell Lymphoma
Participants currently recruited/enrolled
18-125 Years
NCI
Lymphoma
19-C-0112
Phase I/II Study De-intensifying Exposure of Post-transplantation Cyclophosphamide as GVHD Prophylaxis after HLA-haploidentical Hematopoietic Cell Transplantation for Hematologic Malignancies
Participants currently recruited/enrolled
12-125 Years
NCI
Lymphoma
19-C-0103
A Study of Temozolomide, Etoposide, Doxil, Dexamethasone, Ibrutinib, and Rituximab (TEDDI-R) in Aggressive B-cell Lymphomas with Secondary Involvement of the Central Nervous System (CNS)
Participants currently recruited/enrolled
18-125 Years
NCI
Lymphoma
19-C-0085
Phase II Trial of Allogeneic Hematopoietic Cell Transplantation for Peripheral T cell Lymphoma
Clinical hold/Recruitment or enrollment suspended
12-125 Years
NCI
Lymphoma
19-C-0076
A Phase 1 Study of Interleukin-15 in Combination with Avelumab (Bavencio) in Relapsed/Refractory Mature T-cell Malignancies
Completed Study; data analyses ongoing
18-125 Years
NCI
Lymphoma
19-C-0030
A Phase 2 Study of Response-Adapted Therapy with Copanlisib and Rituximab in Untreated Follicular Lymphoma
Participants currently recruited/enrolled
18-125 Years
NCI
Lymphoma
18-C-0126
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)
Completed Study; data analyses ongoing
1-21 Years
NCI
Lymphoma
18-C-0122
Phase 1B Study of Copanlisib in Combination with Nivolumab or with Nivolumab and Ipilimumab
Completed Study; data analyses ongoing
18-125 Years
NCI
Lymphoma
18-C-0059
Phase 1 Dose Escalation Study of CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults with Recurrent or Refractory CD19/CD22-expressing B Cell Malignancies
Participants currently recruited/enrolled
3-39 Years
NCI
Lymphoma
17-H-0118
A Phase II Study Of Ibrutinib, Fludarabine, and Pembrolizumab in High-Risk or Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
No longer recruiting/follow-up only
18-125 Years
NHLBI
Lymphoma
17-C-0164
A Phase 1b/2 Trial of Hu5F9-G4 in Combination with Rituximab or Rituximab + Chemotherapy in Patients with Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma
No longer recruiting/follow-up only
18-125 Years
NCI
Lymphoma
17-C-0156
Longitudinal Sample Collection and Tracking for the Developmental Therapeutics Clinic, National Cancer Institute
Participants currently recruited/enrolled
18-125 Years
NCI
Lymphoma
17-C-0149
Phase 2 Trial of Pembrolizumab in Relapsed and Refractory Gray-Zone Lymphoma (GZL), Primary Central Nervous System Lymphoma (PCNSL),and Other Extranodal Diffuse Large B-cell Lymphomas
No longer recruiting/follow-up only
18-125 Years
NCI
Lymphoma
17-C-0137
Leukapheresis for CAR or Adoptive Cell Therapy Manufacturing
Enrolling by Invitation
3-65 Years
NCI
Lymphoma
17-C-0127
Phase 1b/2 Study of Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma
Participants currently recruited/enrolled
18-125 Years
NCI
Lymphoma
17-C-0125
Phase 2 Trial of Nivolumab in Epstein-Barr Virus (EBV)-Positive Lymphoproliferative Disorders and EBV-Positive Non-Hodgkin Lymphomas
Participants currently recruited/enrolled
12-125 Years
NCI
Lymphoma
17-C-0105
Prospective Study of Clonal Evolution in Follicular Lymphoma
Participants currently recruited/enrolled
18-125 Years
NCI
Lymphoma
17-C-0045
A Phase I Study of Indenoisoquinoline LMP744 in Adults With Relapsed Solid Tumors and Lymphomas
Participants currently recruited/enrolled
18-125 Years
NCI
Lymphoma
16-C-0171
Phase I/II Study of Lenalidomide Combined with Modified DA-EPOCH and Rituximab (EPOCH-R2) in Primary Effusion Lymphoma or KSHV-Associated Large Cell Lymphoma
Participants currently recruited/enrolled
18-125 Years
NCI
Lymphoma
16-C-0066
Phase I Study of MK-3475 (Pembrolizumab) in Patients with Human Immunodeficiency Virus (HIV) and Relapsed/Refractory or Disseminated Malignant Neoplasm
Participants currently recruited/enrolled
18-125 Years
NCI
Lymphoma
16-C-0062
A Phase I Study of Subcutaneous Recombinant Human IL-15 (S.C. Rhil-15) and Alemtuzumab for Patients with Refractory or Relapsed Chronic and Acute Adult T-Cell Leukemia (ATL)
Completed Study; data analyses ongoing
18-125 Years
NCI
Lymphoma
16-C-0061
Biospecimen Procurement for Center for Immuno-Oncology Immunotherapy Protocols
Participants currently recruited/enrolled
18-125 Years
NCI
Lymphoma
16-C-0054
T Cells Expressing a Fully-human Anti- CD19 Chimeric Antigen Receptor for Treating B-cell Malignancies
No longer recruiting/follow-up only
18-73 Years
NCI
Lymphoma
15-H-0172
A Pilot Phase II Study Using Ibrutinib and Short-Course Fludarabine in Previously Untreated Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
No longer recruiting/follow-up only
18-125 Years
NHLBI
Lymphoma
15-H-0016
A Phase II Study Using ACP-196 in Patients with Relapsed/Refractory and Treatment Naive Deletion 17p CLL/SLL: Pharmacodynamic Assessment of BTK Inhibition and Anti-Tumor Response.
No longer recruiting/follow-up only
18-125 Years
NHLBI
Lymphoma
15-C-0078
Safety and Feasibility of Stem Cell Gene Transfer Following R-EPOCH for Non-Hodgkin Lymphoma in AIDS Patients Using Peripheral Blood Stem/Progenitor Cells Treated with a Lentivirus Vector-Encoding Multiple Anti-HIV RNAs
No longer recruiting/follow-up only
18-65 Years
NCI
Lymphoma
15-C-0067
A Phase I/II Open Label, Dose Escalation Study of Palifermin (Kepivance) in Persons Undergoing Unrelated Donor Allogeneic Hematopoietic Cell Transplantation
Participants currently recruited/enrolled
18-125 Years
NCI
Lymphoma
15-C-0029
Phase I Dose Escalation Study of Anti-CD22 Chimeric Receptor T Cells in Pediatric and Young Adults with Recurrent or Refractory CD22-expressing B Cell Malignancies
Participants currently recruited/enrolled
3-39 Years
NCI
Lymphoma
14-N-0061
Noninvasive Pre-surgical Evaluation of Patients with Focal Epilepsy and Establishment of a Normative Imaging Database
Participants currently recruited/enrolled
8-65 Years
NINDS
Zone
14-C-0161
Phase I Trial of the Combination of Bortezomib and Clofarabine in Adults with Refractory Solid Tumors, Lymphomas, or Myelodysplastic Syndromes
Participants currently recruited/enrolled
18-125 Years
NCI
Lymphoma
14-C-0157
Phase 1 Study of Ibrutinib and Immuno-Chemotherapy Using Temozolomide, Etoposide, Doxil, Dexamethasone, Ibrutinib, Rituximab (TEDDI-R) in Primary CNS Lymphoma
Participants currently recruited/enrolled
18-125 Years
NCI
Lymphoma
14-C-0004
A Multicenter Phase 2 Study of the Bruton's Tyrosine Kinase Inhibitor PCI-32765 (Ibrutinib) for Treatment of Relapsed Hairy Cell Leukemia
No longer recruiting/follow-up only
18-125 Years
NCI
Lymphoma
13-N-0135
Pilot Study of Raltegravir, an Integrase Inhibitor, in Human T-Cell Lymphotrophic Virus-1(HTLV-1) Associated Myelopathy, Tropical Spastic Paraparesis (HAM/TSP)
Completed Study; data analyses ongoing
18-125 Years
NINDS
Lymphoma
13-H-0116
A Multicenter Safety Study of Unlicensed, Investigational Cryopreserved Cord Blood Units (CBUs) Manufactured by the National Cord Blood Program (NCBP) and Provided for Unrelated Hematopoietic Stem Cell Transplantation of Pediatric and Adult Patients
Participants currently recruited/enrolled
4-125 Years
NHLBI
Lymphoma
13-C-0118
A Phase I/II Trial of TRC102 (methoxyamine HCl) in Combination with Temozolomide in Patients with Relapsed Solid Tumors and Lymphomas
Participants currently recruited/enrolled
18-125 Years
NCI
Lymphoma
12-H-0035
A Phase II study of Ibrutinib for Patients with Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) Who Need Therapy and are Older than 65 or have a 17p Deletion
No longer recruiting/follow-up only
18-125 Years
NHLBI
Lymphoma
12-C-0193
Lymphoid Malignancies and Precursors: Tissue Acquisition Protocol
Participants currently recruited/enrolled
18-125 Years
NCI
Lymphoma
12-C-0112
Phase I Study of T Cells Expressing an Anti-CD19 Chimeric Receptor in Children and Young Adults with B Cell Malignancies
Completed Study; data analyses ongoing
1-30 Years
NCI
Lymphoma
11-C-0242
Collection of Blood from Patients with Cancer, Other Tumors, or Tumor Predisposition Syndromes for Analysis of Genetic Differences in Drug Disposition
Participants currently recruited/enrolled
3-125 Years
NCI
Lymphoma
11-C-0220
Natural History Study of the KSHV Inflammatory Cytokine Syndrome (KICS) Incorporating Pilot Evaluation of KSHV Targeted Therapies
Participants currently recruited/enrolled
18-125 Years
NCI
Lymphoma
10-H-0141
A Phase II Study of Ofatumumab-Based Induction Chemoimmunotherapy Followed by Consolidation Ofatumumab Immunotherapy in Previously Untreated Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma.
No longer recruiting/follow-up only
18-99 Years
NHLBI
Lymphoma
10-C-0066
A Study of Hairy Cell and other Leukemias with a Focus on Recombinant Immunotoxins for Cancer Treatment
Participants currently recruited/enrolled
18-125 Years
NCI
Lymphoma
10-C-0056
A Phase I Study of Indenoisoquinolines LMP400 and LMP776 in Adults With Relapsed Solid Tumors and Lymphomas
Completed Study; data analyses ongoing
18-125 Years
NCI
Lymphoma
10-C-0054
Administration of Anti-CD19-Chimeric-Antigen-Receptor-Transduced T Cells from the Original Transplant Donor to Patients with Recurrent or Persistent B-Cell Malignancies After Allogeneic Stem Cell Transplantation
No longer recruiting/follow-up only
18-75 Years
NCI
Lymphoma
10-C-0025
Randomized Phase II Trial of Rituximab with Either Pentostatin or Bendamustine for Multiply Relapsed or Refractory Hairy Cell Leukemia
Participants currently recruited/enrolled
18-125 Years
NCI
Lymphoma
10-C-0011
Phase II Trial of Alemtuzumab (Campath) and Dose-Adjusted EPOCH-Rituximab (DA-EPOCH-R) in Relapsed or Refractory Diffuse Large B-Cell and Hodgkin Lymphomas
Completed Study; data analyses ongoing
18-125 Years
NCI
Lymphoma
09-I-0102
Etiology, Pathogenesis, and Natural History of Idiopathic CD4+ Lymphocytopenia
Participants currently recruited/enrolled
18-125 Years
NIAID
Lymphoma
09-C-0053
Autologous and Related/Unrelated Allogeneic Hematopoietic Stem Cell Transplant and Cellular Therapies Data Submission and Research Sample Collection to the Center for International Blood and Marrow Transplant Research (CIBMTR) and the National Marrow Don
Enrolling by Invitation
1-125 Years
NCI
Lymphoma
08-H-0186
Safety and the Anti- Tumor Effects of Escalating Doses of Adoptively Infused Ex Vivo Expanded Autologous Natural Killer (NK) Cells Against Metastatic Cancers or Hematological Malignancies Sensitized to NK-TRAIL Cytotoxicity with Bortezomib
Completed Study; data analyses ongoing
18-70 Years
NHLBI
Lymphoma
07-C-0195
Phase II Trial of Targeted Immune-Depleting Chemotherapy and Reduced-Intensity Allogeneic Hematopoietic Stem Cell Transplantation Using 8/8 and 7/8 HLA-matched Unrelated Donors and Utilizing Two Graft-versus-Host Disease Prophylaxis Regimens for the Trea
Completed Study; data analyses ongoing
18-74 Years
NCI
Lymphoma
06-I-0015
Screening Protocol for Genetic Diseases of Lymphocyte Homeostasis and Programmed Cell Death
Participants currently recruited/enrolled
0-125 Years
NIAID
Lymphoma
06-C-0213
Tissue Procurement Protocol for the Developmental Therapeutics Clinic, National Cancer Institute (NCI)
Participants currently recruited/enrolled
0-125 Years
NCI
Lymphoma
06-C-0150
A Phase II Clinical Trial of Anti-Tac(Fv)-PE38 (LMB-2) Immunotoxin for CD25 Positive Hairy Cell Leukemia
No longer recruiting/follow-up only
18-125 Years
NCI
Lymphoma
05-CH-0037
The Effects of Hydrocortisone, Melatonin, and Placebo on Symptoms of Jet Lag
Completed Study; data analyses ongoing
18-65 Years
NICHD
Zone
05-C-0252
Phase III Randomized Study of R-CHOP v. Dose-Adjusted EPOCH-R with Molecular Profiling in Untreated de Novo Diffuse Large B-Cell Lymphomas
Completed Study; data analyses ongoing
18-125 Years
NCI
Lymphoma
04-C-0102
Hematologic Malignancy Biology Study
Enrolling by Invitation
1-75 Years
NCI
Lymphoma
02-I-0286
Efficacy of Tyrosine Kinase Inhibition in Reducing Eosinophilia in Patients with Myeloid and/or Steroid-Refractory Hypereosinophilic Syndrome
Participants currently recruited/enrolled
2-125 Years
NIAID
Lymphoma
02-H-0250
A Phase I/II Study of HLA-matched Mobilized Peripheral Blood Hematopoietic Stem Cell Transplantation for Advanced Mycosis Fungoides/Sezary Syndrome Using Nonmyeloablative Conditioning with Campath-1H
Completed Study; data analyses ongoing
18-125 Years
NHLBI
Lymphoma
02-C-0210
Clinical, Laboratory, and Epidemiologic Characterization of Individuals and Families at High Risk of Blood and Lymph Node Malignancy
Participants currently recruited/enrolled
0-125 Years
NCI
Lymphoma
01-I-0238
Host Response to Infection and Treatment in Leishmania Infection of Humans
Participants currently recruited/enrolled
3-100 Years
NIAID
Splenic
01-C-0038
Collection of Blood, Bone Marrow, Tumor, or Tissue Samples from Patients with HIV Infection, KSHV Infection, Viral-Related Pre-Malignant Lesions, and/or Cancer
Participants currently recruited/enrolled
18-125 Years
NCI
Lymphoma
01-C-0030
Short-Course EPOCH - Rituximab in Untreated CD-20+ HIV-Associated Lymphomas
No longer recruiting/follow-up only
18-125 Years
NCI
Lymphoma
99-H-0050
Non-Myeloablative Allogeneic Peripheral Blood Mobilized Hematopoietic Precursor Cell Transplantation for Hematologic Malignancies in High Risk Patients and in Patients with Debilitating Hematologic Diseases
Completed Study; data analyses ongoing
2-80 Years
NHLBI
Lymphoma
96-C-0071
Follow-up for Patients Previously Enrolled on the Center for Cancer Research Protocols
No longer recruiting/follow-up only
0-125 Years
NCI
Lymphoma
94-C-0074
Treatment and Natural History Study of Lymphomatoid Granulomatosis
Participants currently recruited/enrolled
12-125 Years
NCI
Lymphoma
93-I-0063
Study of the Immunopathogenesis, Natural History, and Genetics of Autoimmune Lymphoproliferative Syndrome (ALPS) Associated with an Expansion of CD4-8-/TCR alpha/beta+ T Cells
Participants currently recruited/enrolled
0-99 Years
NIAID
Lymphoma